Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24238806 | 0.83 | LMNA (0.36) | MAPTLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL24238815 | 0.82 | MEN1 (0.36) | MAPTLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL22045138 | 0.75 | KCNQ3 (0.41) | MAPTMEN1KMT2A | |
| SCHEMBL24238756 | 0.73 | HRH3 (0.41) | LMNACHRM2CHRM4CHRM5THRB | |
| SCHEMBL29993409 | 0.73 | KDM4E (0.44) | MAPTLMNAOPRK1MEN1KMT2A | |
| SCHEMBL28601758 | 0.73 | KDM4E (0.44) | MAPTLMNAOPRK1MEN1KMT2A | |
| SCHEMBL18179213 | 0.63 | PDGFRB (0.39) | MAPTLMNAKMT2A | |
| SCHEMBL31386217 | 0.63 | GSK3B (0.37) | MAPTLMNA | |
| SCHEMBL7920331 | 0.63 | KDM4E (0.49) | MAPTLMNAKMT2A | |
| SCHEMBL31444532 | 0.60 | TSHR (0.40) | MAPTLMNAOPRK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | VIM, MAVS, VARS1 | MAPT 2447/4885LMNA 845/4885CHRM2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.